1. [NDM-1: the superbug?].
- Author
-
Pittalis S, Ferarro F, and Puro V
- Subjects
- Abscess microbiology, Anti-Bacterial Agents pharmacology, Buttocks, Colistin pharmacology, Drug Resistance, Multiple, Bacterial, Humans, India, Klebsiella Infections complications, Klebsiella Infections microbiology, Klebsiella pneumoniae enzymology, Klebsiella pneumoniae isolation & purification, Male, Microbial Sensitivity Tests, Middle Aged, Sweden, Travel, Treatment Outcome, beta-Lactamases drug effects, Abscess drug therapy, Anti-Bacterial Agents therapeutic use, Colistin therapeutic use, Diabetes Complications, Klebsiella Infections drug therapy, Klebsiella pneumoniae drug effects, beta-Lactamases metabolism
- Abstract
A novel type of carbapenemase, New Delhi metallo beta-lactamase 1 (NDM 1), was first identified in 2008 in two Enterobacteriacea isolates, both recovered from a Swedish patient transferred from India. The emergence of NDM 1 is now reported from all continents, often in patients with a history of travel or hospitalization in the Indian subcontinent. The NDM 1 producing Gram-negative bacteria are mainly Enterobacteriaceae, which can cause colonization or fatal infections, with worrying antimicrobial susceptibility profiles: some isolates have developed resistance to practically all available antibiotics. Is the NDM-1 the super-bug? Are we in the post-antibiotic era? This review is a summary of currently available knowledge of NDM-1 that draws attention to future antimicrobial resistance scenarios.
- Published
- 2011